We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Australia Warns of Melanoma Risks When Using MS Drug
Australia Warns of Melanoma Risks When Using MS Drug
Australia’s Therapeutic Goods Administration said recently it is evaluating the potential safety risks with Biogen Idec’s multiple sclerosis drug Tysabri following reports of melanoma in patients using the drug.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor